Astria Therapeutics (ATXS) Competitors $6.59 +0.41 (+6.63%) Closing price 04:00 PM EasternExtended Trading$6.59 0.00 (0.00%) As of 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATXS vs. SDGR, AVDL, ARDX, JANX, HROW, VERA, AMPH, SNDX, ETNB, and COGTShould you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Schrodinger (SDGR), Avadel Pharmaceuticals (AVDL), Ardelyx (ARDX), Janux Therapeutics (JANX), Harrow (HROW), Vera Therapeutics (VERA), Amphastar Pharmaceuticals (AMPH), Syndax Pharmaceuticals (SNDX), 89BIO (ETNB), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. Astria Therapeutics vs. Its Competitors Schrodinger Avadel Pharmaceuticals Ardelyx Janux Therapeutics Harrow Vera Therapeutics Amphastar Pharmaceuticals Syndax Pharmaceuticals 89BIO Cogent Biosciences Schrodinger (NASDAQ:SDGR) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership. Does the media favor SDGR or ATXS? In the previous week, Schrodinger had 2 more articles in the media than Astria Therapeutics. MarketBeat recorded 7 mentions for Schrodinger and 5 mentions for Astria Therapeutics. Schrodinger's average media sentiment score of 1.52 beat Astria Therapeutics' score of 0.99 indicating that Schrodinger is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Schrodinger 6 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Astria Therapeutics 2 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, SDGR or ATXS? Schrodinger has a beta of 1.79, suggesting that its stock price is 79% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Which has stronger earnings and valuation, SDGR or ATXS? Astria Therapeutics has lower revenue, but higher earnings than Schrodinger. Schrodinger is trading at a lower price-to-earnings ratio than Astria Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSchrodinger$207.54M6.78-$187.12M-$2.48-7.71Astria TherapeuticsN/AN/A-$94.26M-$2.01-3.28 Do institutionals & insiders hold more shares of SDGR or ATXS? 79.1% of Schrodinger shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 21.0% of Schrodinger shares are owned by insiders. Comparatively, 4.5% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Do analysts recommend SDGR or ATXS? Schrodinger presently has a consensus price target of $27.83, suggesting a potential upside of 45.65%. Astria Therapeutics has a consensus price target of $29.00, suggesting a potential upside of 340.06%. Given Astria Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Astria Therapeutics is more favorable than Schrodinger.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Schrodinger 0 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.67Astria Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 Is SDGR or ATXS more profitable? Astria Therapeutics has a net margin of 0.00% compared to Schrodinger's net margin of -76.22%. Schrodinger's return on equity of -45.70% beat Astria Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Schrodinger-76.22% -45.70% -24.81% Astria Therapeutics N/A -56.39%-36.08% SummaryAstria Therapeutics beats Schrodinger on 9 of the 16 factors compared between the two stocks. Get Astria Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ATXS vs. The Competition Export to ExcelMetricAstria TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$371.94M$3.10B$5.69B$9.68BDividend YieldN/A2.28%6.66%4.54%P/E Ratio-3.2820.9982.6526.40Price / SalesN/A358.86518.27206.18Price / CashN/A43.5325.7028.92Price / Book1.669.8811.246.06Net Income-$94.26M-$53.38M$3.28B$266.05M7 Day Performance-1.20%-0.14%0.15%-0.07%1 Month Performance0.46%9.18%8.34%5.83%1 Year Performance-46.12%7.53%54.21%17.88% Astria Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ATXSAstria Therapeutics1.9764 of 5 stars$6.59+6.6%$29.00+340.1%-49.5%$371.94MN/A-3.2830News CoverageSDGRSchrodinger2.5797 of 5 stars$19.54-3.8%$27.83+42.4%-7.2%$1.50B$207.54M-7.88790Analyst DowngradeAVDLAvadel Pharmaceuticals3.0559 of 5 stars$14.81-2.8%$19.67+32.8%-2.7%$1.48B$169.12M-493.6770ARDXArdelyx4.3357 of 5 stars$6.06-0.8%$11.50+89.8%+2.9%$1.47B$333.61M-26.3590News CoverageJANXJanux Therapeutics3.1915 of 5 stars$23.01-5.3%$86.90+277.7%-51.6%$1.46B$10.59M-12.7830News CoveragePositive NewsHROWHarrow3.3147 of 5 stars$37.36-4.5%$64.67+73.1%-3.6%$1.45B$227.66M-149.44180VERAVera Therapeutics2.7514 of 5 stars$21.34-5.4%$63.00+195.2%-42.8%$1.44BN/A-5.9640News CoveragePositive NewsAMPHAmphastar Pharmaceuticals3.3693 of 5 stars$29.83-2.2%$31.50+5.6%-37.2%$1.42B$731.97M11.172,028Positive NewsSNDXSyndax Pharmaceuticals4.2851 of 5 stars$15.66-3.6%$38.00+142.7%-20.5%$1.40B$23.68M-4.03110Positive NewsETNB89BIO2.3647 of 5 stars$9.10-3.5%$26.63+192.6%-4.9%$1.40BN/A-2.5240News CoveragePositive NewsAnalyst ForecastCOGTCogent Biosciences2.9584 of 5 stars$11.79-2.7%$19.00+61.2%+12.5%$1.38BN/A-6.6280News CoveragePositive News Related Companies and Tools Related Companies Schrodinger Competitors Avadel Pharmaceuticals Competitors Ardelyx Competitors Janux Therapeutics Competitors Harrow Competitors Vera Therapeutics Competitors Amphastar Pharmaceuticals Competitors Syndax Pharmaceuticals Competitors 89BIO Competitors Cogent Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ATXS) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, an...Stansberry Research | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Astria Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Astria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ATXS Stock Alerts